Fosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection

Bulletin Express03-20

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; HKEX: 02196, SSE: 600196) announced that its wholly-owned subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has secured National Medical Products Administration (NMPA) approval for Sodium Thiosulfate Injection, targeting cyanide as well as arsenic, mercury, lead, bismuth and iodine poisoning cases. The approval expands the group’s emergency medicine portfolio and grants a drug approval number of “Guo Yao Zhun Zi H202636372.”

The newly approved product is a Category 3 chemical formulation with a specification of 4 ml: 1 g per vial. Chongqing Carelife is the marketing authorisation holder, while manufacturing will be undertaken by Yaopharma Co., Ltd.

Fosun Pharma has invested approximately RMB1.87 million in the compound’s research and development up to February 2026. According to IQVIA CHPA data, China’s market (excluding Hong Kong, Macau and Taiwan) for Sodium Thiosulfate formulations reached about RMB431.00 million in 2025, underscoring sizeable commercial potential within the antidote segment.

Management expects the approval to strengthen the group’s product pipeline; however, it cautions that actual sales will depend on medical demand, competitive dynamics and channel penetration, factors that could introduce variability to future revenue contributions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144779449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144779449","market":"hk","top_or_hot":-1,"title":"Fosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; HKEX: 02196, SSE: 600196) announced that its wholly-owned subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has secured National Medical Products Administration (NMPA) approval for Sodium Thiosulfate Injection, targeting cyanide as well as arsenic, mercury, lead, bismuth and iodine poisoning cases. The approval expands the group’s emergency medicine portfolio and grants a drug approval number of “Guo Yao Zhun Zi H202636372.”</p>\n<p>The newly approved product is a Category 3 chemical formulation with a specification of 4 ml: 1 g per vial. Chongqing Carelife is the marketing authorisation holder, while manufacturing will be undertaken by Yaopharma Co., Ltd.</p>\n<p>Fosun Pharma has invested approximately RMB1.87 million in the compound’s research and development up to February 2026. According to IQVIA CHPA data, China’s market (excluding Hong Kong, Macau and Taiwan) for Sodium Thiosulfate formulations reached about RMB431.00 million in 2025, underscoring sizeable commercial potential within the antidote segment.</p>\n<p>Management expects the approval to strengthen the group’s product pipeline; however, it cautions that actual sales will depend on medical demand, competitive dynamics and channel penetration, factors that could introduce variability to future revenue contributions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-20 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; HKEX: 02196, SSE: 600196) announced that its wholly-owned subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has secured National Medical Products Administration (NMPA) approval for Sodium Thiosulfate Injection, targeting cyanide as well as arsenic, mercury, lead, bismuth and iodine poisoning cases. The approval expands the group’s emergency medicine portfolio and grants a drug approval number of “Guo Yao Zhun Zi H202636372.”</p>\n<p>The newly approved product is a Category 3 chemical formulation with a specification of 4 ml: 1 g per vial. Chongqing Carelife is the marketing authorisation holder, while manufacturing will be undertaken by Yaopharma Co., Ltd.</p>\n<p>Fosun Pharma has invested approximately RMB1.87 million in the compound’s research and development up to February 2026. According to IQVIA CHPA data, China’s market (excluding Hong Kong, Macau and Taiwan) for Sodium Thiosulfate formulations reached about RMB431.00 million in 2025, underscoring sizeable commercial potential within the antidote segment.</p>\n<p>Management expects the approval to strengthen the group’s product pipeline; however, it cautions that actual sales will depend on medical demand, competitive dynamics and channel penetration, factors that could introduce variability to future revenue contributions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1144779449","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144779449","pubTimestamp":1774004587,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; HKEX: 02196, SSE: 600196) announced that its wholly-owned subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has secured National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(02196)子公司硫代硫酸钠注射液获NMPA绿灯","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; HKEX: 02196, SSE: 600196) announced that its wholly-owned subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has secured National Medical Products Administration (NMPA) approval for Sodium Thiosulfate Injection, targeting cyanide as well as arsenic, mercury, lead, bismuth and iodine poisoning cases. The approval expands the group’s emergency medicine portfolio and grants a drug approval number of “Guo Yao Zhun Zi H202636372.”\nThe newly approved product is a Category 3 chemical formulation with a specification of 4 ml: 1 g per vial. Chongqing Carelife is the marketing authorisation holder, while manufacturing will be undertaken by Yaopharma Co., Ltd.\nFosun Pharma has invested approximately RMB1.87 million in the compound’s research and development up to February 2026. According to IQVIA CHPA data, China’s market (excluding Hong Kong, Macau and Taiwan) for Sodium Thiosulfate formulations reached about RMB431.00 million in 2025, underscoring sizeable commercial potential within the antidote segment.\nManagement expects the approval to strengthen the group’s product pipeline; however, it cautions that actual sales will depend on medical demand, competitive dynamics and channel penetration, factors that could introduce variability to future revenue contributions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144779449","isCrawlerRequest":true}